About CUTISS
CUTISS is a company based in Zurich (Switzerland) founded in 2017 by Daniela Marino and Fabienne Hartmann-Fritsch. It operates as a Product-as-a-Service. CUTISS has raised $94.37 million across 13 funding rounds from investors including Zurcher Kantonalbank, European Union and GISEV. CUTISS offers products and services including denovoSkin™. CUTISS operates in a competitive market with competitors including Humacyte, Tissue Regenix, Acera Surgical, Solsys Medical and Heartseed, among others.
- Headquarter Zurich, Switzerland
- Founders Daniela Marino, Fabienne Hartmann-Fritsch
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cutiss Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$94.37 M (USD)
in 13 rounds
-
Latest Funding Round
$39.01 M (USD), Series C
Sep 10, 2025
-
Investors
Zurcher Kantonalbank
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CUTISS
CUTISS offers a comprehensive portfolio of products and services, including denovoSkin™.
Personalized skin tissue therapy is developed for surgeries.
People of CUTISS
Unlock access to complete
Funding Insights of CUTISS
CUTISS has successfully raised a total of $94.37M across 13 strategic funding rounds. The most recent funding activity was a Series C round of $39.01 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CUTISS
CUTISS has secured backing from 10 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, European Union and GISEV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Cherry Bay Capital Group is engaged in wealth advisory and investment services.
|
Locked | Locked | Locked |
Investor details for CUTISS
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CUTISS
Investment portfolio details for CUTISS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CUTISS
Detailed financials for CUTISS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cutiss Comparisons
Peer comparison for CUTISS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CUTISS
CUTISS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Humacyte, Tissue Regenix, Acera Surgical, Solsys Medical and Heartseed, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Human tissue-based products are developed for vascular disease applications.
|
|
| Locked | Locked | Locked |
Developer of regenerative medical devices by using cell technology
|
|
| Locked | Locked | Locked |
Synthetic electrospun scaffolds are provided for regenerative medical uses.
|
|
| Locked | Locked | Locked |
Human skin allografts and dressings for wound care are supplied.
|
|
| Locked | Locked | Locked |
Developer of myocardial regenerative medicine for treating heart diseases
|
Detailed competitors of CUTISS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cutiss
Complete news archive for CUTISS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CUTISS
CUTISS was founded in 2017.
CUTISS is headquartered in Zurich, Switzerland.
Daniela Marino is the current CEO of CUTISS. They have also founded this company.
CUTISS is a funded company, having raised a total of $94.37M across 13 funding rounds to date.
Skin tissue therapeutics are pioneered by CUTISS, a TechBio company focused on bioengineering. Personalized therapy, denovoSkin, is manufactured for skin surgeries including burns and reconstructive applications. Solutions are produced at a GMP facility in Zurich, Switzerland, using automated, scalable platforms. The technology supports regenerative medicine, space health research, and industrial bioengineered tissues. Expansion into other tissues like gums and cornea is targeted for accessible treatments.
CUTISS's top competitors include Humacyte, Acera Surgical and Heartseed.
CUTISS offers denovoSkin™.
CUTISS has 10 investors. Key investors include Zurcher Kantonalbank, European Union, GISEV, Rode Kruis Ziekenhuis, and Cherry Bay Capital Group.